🌅 Today's Morning Call
|
S&P Futures
7,173.75
▼ -9.00 (-0.13%)
|
Nasdaq Futures
27,255.00
▼ -30.00 (-0.11%)
|
Dow Futures
49,294.00
▼ -86.00 (-0.17%)
|
|
10Y Treasury
4.35%
▲ +0.02%
|
US Dollar
98.72
▲ +0.05 (+0.05%)
|
Bitcoin
$77,513
▲ +$1,197 (+1.57%)
|
Data as of 8:07 AM ET
Good morning! Wednesday, April 29 is arriving with futures pointing modestly lower across the board, but the real action this morning is unfolding in the pharmaceutical sector, where a string of impressive earnings beats is stealing the spotlight. AbbVie, Regeneron, and Pfizer each delivered news overnight that has traders rethinking where the resilience in this market actually lives. Here's your morning rundown.
👀 What to Watch Today
Today's session will be shaped heavily by the continued flow of earnings results, with traders keeping close tabs on any forward guidance that touches on tariff exposure and consumer spending trends. The economic calendar also deserves attention, as the April consumer confidence reading and the latest JOLTS job openings data are both due out this morning, two data points the Fed is watching closely before its next policy meeting.On the corporate side, keep an eye on Cognizant (CTSH), which spooked IT-sector investors overnight by projecting weaker-than-expected Q3 revenue. That kind of cautious tone from a major technology services firm could ripple into adjacent names like Accenture and Infosys throughout the day.
The 10-year Treasury yield is ticking up modestly to 4.35%, and the dollar index (DXY) is nudging higher at 98.72. Neither move is dramatic, but together they set a slightly cautious backdrop heading into the open, especially for growth and rate-sensitive names.
Your Phone Is Smarter Than Your Inbox
Markets move fast. By the time you open your email, the opportunity is already gone. That's why we built Financial Edge Daily SMS — market insights, stocks on our radar, and plays worth considering, delivered straight to your phone. No fluff, no noise. No charge.
Text Me the Alerts🌏 Overnight Recap
Overnight, UBS (UBS) reported a Q1 net profit of $3.04 billion, comfortably clearing the analyst consensus estimate of $2.33 billion. That is a meaningful beat for a bank still navigating its post-Credit Suisse integration, and it adds a constructive data point to the global financials picture heading into today's session.Across the Channel, AstraZeneca (AZN) grabbed headlines after UK Prime Minister Keir Starmer announced a 300 million pound, roughly $405 million, investment commitment in the United Kingdom. The move is notable given the current climate of global trade uncertainty, and it signals that at least one major multinational is doubling down on domestic manufacturing capacity.
In the deal space, Italian pharma firm Chiesi Group announced it will acquire US-listed KalVista Pharmaceuticals (KALV) in an all-cash transaction worth approximately $1.9 billion. That kind of premium buyout tends to lift sentiment across smaller biotech names, so watch mid-cap pharma early in the session for any sympathy moves.
Sponsored Content
Satellite Confirms: Elon Musk Activating Strange 'Dark Energy' Across U.S. South
Confirmed by satellites 300 miles above the Earth's surface... Elon Musk is rolling out a breakthrough technology that could replace our need for foreign oil and ignite a $10 trillion boom a small group of stocks.
📊 Pre-Market Movers
KalVista Pharmaceuticals (KALV) is the standout pre-market mover by a wide margin, surging on the $1.9 billion all-cash takeover bid from Italy's Chiesi Group. Deals of this size and at this kind of premium tend to send traders hunting for the next acquisition target in the specialty pharma space.AbbVie (ABBV) and Regeneron (REGN) are both trading higher in the pre-market after delivering clean earnings beats. ABBV's growth in Skyrizi and Rinvoq is convincingly filling the Humira revenue gap, while REGN's Dupixent franchise continues to print like a machine. Both stocks are drawing fresh interest before the bell.
On the downside, Cognizant (CTSH) is under pressure after guiding for a revenue miss driven by cautious enterprise IT budgets. Etsy (ETSY) is bucking the trend with a pre-market gain after beating revenue expectations, crediting an uptick in active buyers and stronger gross merchandise sales as a bright spot in the consumer spending picture.
🔍 Today's Watchlist
- ABBV: Skyrizi and Rinvoq momentum more than covers the Humira decline, watch for analyst target revisions at the open
- REGN: Dupixent demand drove another earnings beat, forward guidance on its cancer pipeline could set the tone for biotech today
- CTSH: Cautious Q3 revenue outlook signals client belt-tightening on IT spend, a potential headwind for the broader tech services sector
- 10-Year Treasury at 4.35%: Yield creep is subtle but persistent, keep an eye on rate-sensitive REITs and utilities if the move accelerates
- KALV: All-cash $1.9B acquisition by Chiesi could spark a biotech M&A sentiment lift, scan small-cap pharma for unusual options activity
Sponsored Content
I've Rarely Seen This With Silver
This combination – 20% dividends + 68% share appreciation – never happens with silver. But it is now possible thanks to a new ETF that delivers the best of worlds.
🎯 The Morning Playbook
The pre-market setup today is a tale of two markets. Macro futures are soft, yields are creeping, and the dollar is firm, none of which screams risk-on. But underneath that, you have a pharma and biotech earnings wave that is genuinely impressive, and that divergence is worth paying attention to.If you are a sector-focused trader, this morning's data makes a compelling case for healthcare as a relative-strength pocket in a choppy tape. ABBV, REGN, and even PFE are all working from a position of fundamental strength, and that tends to attract defensive rotation when broader sentiment is uncertain.
Finally, do not overlook the macro data drops this morning. Consumer confidence and job openings numbers hitting before midday could quickly shift the narrative away from earnings and back toward the Fed. Stay nimble, watch the bond market for cues, and remember that a soft pre-market does not always translate into a soft close.